2019 International Meeting on the Molecular Biology of Hepatitis B Viruses

摘要/总结 B型肝炎病毒（HBV）是一种主要的全球公共卫生威胁，全世界有超过2.9亿人感染HBV 每年有超过887，000人死亡。HBV引起几乎40%的肝细胞癌 癌症病例，这是世界范围内癌症相关死亡率的第二大原因。当前 预防性疫苗对已确定的慢性感染没有影响，也无法治愈。 一年一度的国际HBV分子病毒学会议是唯一的论坛，聚集了 国际社会的研究人员谁研究的分子生物学和发病机制的HBV和密切 丁型肝炎病毒（HDV）。2019年，这一会议将首次在澳大利亚举行， 慢性B型肝炎高度流行的亚洲/太平洋地区，受影响的人数超过1.1亿。 重要的是，澳大利亚土著居民的慢性HBV感染率比非土著居民高出10倍， 原因不明。 我们要求资助年轻科学家参加2019年世界科学大会的差旅费。 国际B型肝炎病毒分子生物学会议。2019年会议将提供 科学交流和传播最新研究信息的论坛，包括讨论 关于潜在治愈HBV和HDV感染的新治疗策略。估计有500-600人 代表们将参加2019年的会议，这将标志着这一重要聚会35周年。 会议将包括8个口头科学会议，2个海报会议和一个小型研讨会，重点是 关于B型肝炎治疗的会议将在主要会议之后举行。科学互动也将得到促进 来自HBV领域以外的专家的3个主题演讲，他们将带来不同的观点。重要的是，在 在2019年国际HBV会议上，我们将首次举办一个公共论坛， 国际乙肝会议可以与公众、媒体、学生和成员接触， 讨论HBV、慢性疾病、新的治疗方法和治疗方法， 外行术语论坛将在主要会议结束时举行，以确保不与 在科学会议上发言。 同过去一样，为尽量减少会议费用作出了巨大努力， 自2005年以来，会议的组织一直得到B型肝炎基金会的支持，包括 向少数群体代表人数不足的大学宣传会议。以便允许 初级和少数民族研究人员的参与，美国国立卫生研究院的支持，以帮助支付 2019年会议的费用已提出要求。这笔资金将用于确保出席和介绍， 早期职业研究人员，特别是来自低收入和中等收入国家以及弱势群体的研究人员 包括澳大利亚原住民。

ABSTRACT/SUMMARY Hepatitis B virus (HBV) is a major global public health threat with over 290 million people worldwide chronically infected and over 887,000 deaths per year. HBV causes almost 40% of all hepatocellular carcinoma cases, which is the 2nd leading cause of cancer-related mortality worldwide. The current prophylactic vaccine has no impact on established chronic infection and there is no cure. The annual International HBV Molecular Virology Meeting is the only forum that gathers the international community of researchers who study molecular biology and pathogenesis of HBV and the closely associated hepatitis delta virus (HDV). In 2019, this meeting will be held for the first time in Australia, in the Asia/Pacific region where chronic hepatitis B is highly endemic, with over 110 million people affected. Importantly, rates of chronic HBV are up to ten times higher in Indigenous Australians than non-Indigenous, for reasons that are unclear. We request funding to support travel expenses for young scientists to participate in the 2019 International Meeting on the Molecular Biology of Hepatitis B Viruses. The 2019 meeting will provide the forum for scientific exchange and dissemination of the latest research information, including discussions regarding new therapeutic strategies for potentially curing HBV and HDV infections. An estimated 500-600 delegates will attend the 2019 meeting, which will mark the 35th anniversary of this important gathering. The meeting will consist of 8 oral scientific sessions, 2 poster sessions, and a mini-symposium focused on hepatitis B cure that will be held following the main meeting. The scientific interactions will also be facilitated by 3 keynote addresses from experts outside the HBV field who will bring different perspectives. Importantly, at the 2019 International HBV meeting we will hold a public forum for the first time where leading scientists from the International HBV meeting can engage with members of the general public, media, students and members of the HBV affected community to discuss HBV, chronic disease, new treatments, and approaches to cure in lay terms. The Forum will be held at the conclusion of the main meeting to ensure it does not clash with presentations at the Scientific meeting. As in the past, great effort has been made to minimize the cost of the meeting, with a major strength of the meeting organization being continual support from the Hepatitis B Foundation since 2005, including publicizing the meeting to universities with large numbers of underrepresented minorities. In order to allow the participation of junior and minority investigators, support from the National Institutes of Health to help defray the costs of the 2019 meeting is requested. This funding will be used to ensure attendance and presentation by early career researchers, particularly from low and middle-income countries, as well as disadvantaged groups including Indigenous Australians.